Customising radiotherapy in stage II breast cancer after primary chemotherapy

Neoadjuvant chemotherapy for breast cancer management is increasingly used in clinical practice for large or locoregionally advanced tumours. Tumour response after neoadjuvant chemotherapy has a prognostic impact on survival.1,2 Consequently, de-escalating subsequent treatment modalities could be considered based on tumour response to neoadjuvant chemotherapy, in particular adjuvant radiotherapy, to avoid unnecessary treatment-related complications.